Clinical Utility of Clopidogrel Drug Response Testing
Clopidogrel (brand name Plavix) is one of the most widely prescribed antiplatelet drugs in the world, used to prevent blood clots in patients with heart disease, stroke, or peripheral artery disease. Yet a significant proportion of patients — estimated at 20–30% — do not respond adequately to clopidogrel. This phenomenon, known as clopidogrel resistance, can lead to treatment failure and serious cardiovascular events.
Why Does Clopidogrel Resistance Occur?
Clopidogrel is a prodrug — it must be converted into its active form in the liver before it can inhibit platelet aggregation. This conversion is primarily carried out by the enzyme CYP2C19. Genetic variants in the CYP2C19 gene significantly affect how efficiently this conversion occurs:
Poor metabolisers (carrying two loss-of-function alleles, e.g., *2/*2) — Produce very little active clopidogrel. At high risk of treatment failure and recurrent cardiovascular events
Intermediate metabolisers (one loss-of-function allele) — Reduced drug activation; moderately elevated risk
Normal/extensive metabolisers — Standard drug response; clopidogrel works as expected
Ultrarapid metabolisers (gain-of-function allele, *17) — Enhanced drug activation; may have increased bleeding risk
Clinical Implications
The US FDA has issued a black box warning for clopidogrel, noting that poor metabolisers may not receive the full benefit of the drug. For patients undergoing percutaneous coronary intervention (PCI/stenting), CYP2C19 poor metaboliser status is associated with significantly higher rates of major adverse cardiovascular events (MACE).
Alternative antiplatelet agents — such as prasugrel or ticagrelor — are not dependent on CYP2C19 activation and may be more appropriate for poor metabolisers.
The Case for Pharmacogenomic Testing
CYP2C19 genotyping before initiating clopidogrel therapy allows clinicians to:
Identify poor and intermediate metabolisers who are unlikely to benefit from clopidogrel
Select alternative antiplatelet therapy proactively, before a cardiovascular event occurs
Personalise antiplatelet dosing for ultrarapid metabolisers at bleeding risk
This is a clear example of pharmacogenomics delivering direct, actionable clinical value — the right drug, for the right patient, at the right dose.
Know Your Drug Response Profile Genetically
Genomepatri by MapmyGenome includes pharmacogenomic insights — covering how your body metabolises common cardiovascular, psychiatric, and other medications — so your doctor can prescribe the right drug at the right dose for your unique genetic profile.
